Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>JPM Sees CN Healthcare Sector Pullback as Entry Opportunity, Raises TPs for INNOVENT BIO/ WUXI XDC
Recommend 10 Positive 10 Negative 5 |
||||
|
||||
|
According to JPMorgan's research report, while the Chinese healthcare sector retreated from its highs in September and October due to the results of the national medical insurance drug list price negotiations and subsequent profit-taking, the broker believes the industry's fundamentals remain unchanged, and the recent weakness provides a good entry for 2026. In terms of stock selection, JPMorgan favors biotechnology and CXO, with top picks including INNOVENT BIO (01801.HK), SKB BIO-B (06990.HK), WUXI APPTEC (02359.HK), and WUXI XDC (02268.HK). It is also bullish about MEDBOT-B (02252.HK) in the medical technology sector. JPMorgan cut its target price for AKESO (09926.HK) from HKD166 to HKD149 but kept the Overweight rating unchanged. In contrast, its target price for INNOVENT BIO was slightly raised from HKD110 to HKD111, with an unchanged Overweight rating. WUXI XDC's target price was lifted from HKD74 to HKD82, with a rating of Overweight intact. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
